American Association for Cancer Research
Browse
10780432ccr132626-sup-relatedarticle.html (0.94 kB)

Related Article from Pertuzumab Protects the Achilles' Heel of Trastuzumab—Emtansine

Download (0.94 kB)
dataset
posted on 2023-03-31, 17:26 authored by William R. Gwin, Neil L. Spector
Related Article from Pertuzumab Protects the Achilles' Heel of Trastuzumab—Emtansine

History

ARTICLE ABSTRACT

Trastuzumab emtansine (T-DM1) represents a significant advancement in the treatment of HER2+ breast cancers. Its clinical efficacy however will be limited by the development of therapeutic resistance. In this report, the HER3 ligand neuregulin is shown to mediate T-DM1 resistance, which was overcome by administration of pertuzumab, a steric inhibitor of HER2 dimerization. Clin Cancer Res; 20(2); 278–80. ©2013 AACR.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC